Litigation

Amneal Pharmaceuticals LLC et al. v. Jazz Pharmaceuticals, Inc.

final written decision; affirmed on appeal

IPR2015-00545

Filed
2015-01-08
Terminated
2016-07-27

Patents at issue (1)

Summary

Inter partes review of U.S. 8,589,182 B1. The PTAB held all challenged claims unpatentable as obvious over FDA Xyrem advisory-committee materials; rehearing was denied and the decision was affirmed by the Federal Circuit.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).